A Phase 2 interventional study of GE-287 and Vizamyl in Cognitive Dysfunction, sponsored by GE Healthcare. Recruiting at 6 sites in United States. Open to participants aged 50 Years to 110 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by GE Healthcare · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,422 studies in Cognitive Dysfunction with a site in United States — 329 open to participants now, 432 under way, 13 of them phase 3. Cognitive Dysfunction · United States.
Among the 1,422 studies in Cognitive Dysfunction with a site in United States, this one is the 900th largest by planned enrollment of the 1,146 interventional ones that give a count, is one of 96 that started in 2026, is one of 198 in phase 2, reaches primary completion later than 165 of the 431 other live ones, and was the 1,413th registered.
3,883 studies on the registry are indexed under Cognitive Dysfunction; 1,121 are open to participants now.
Browse Cognitive Dysfunction studies →329 of the 1,422 studies in Cognitive Dysfunction with a site in United States are open now. Recruiting first, the newest first:
National Institute of Mental Health (NIMH) · Sites in United States
Ages 50–100 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 65+
University of Pittsburgh · Sites in United States
Ages 65+
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 50–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 752 Cognitive Dysfunction studies recruiting now, 362 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 50 Years to 110 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,422 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 126 · Phase 2 234 · Phase 3 54 · Phase 4 58
First in 1993; this study’s year is marked. 96 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 64 across 2,802 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 59 across the 1,146 interventional studies, 150 across the 271 observational. Of the 889 that completed or were terminated, 378 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
209 of 1,422 have an industry lead sponsor. The 10 most frequent:
GE Healthcare is the lead sponsor of 176 studies on the registry; 21 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
GE Healthcare has 6 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
174 of the studies in Cognitive Dysfunction with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT06950190Phase 3Ellis MedicineEvaluating Cognitive Changes on Patients in Chemotherapy (ECCPC) | 2027-02-20 |
| NCT03560960Boston UniversityMulti-Center Development of a Novel Diagnostic Test for Alzheimer's Disease | 2026-11 |
Add all 174 to your calendar (.ics) → With an account.
Among the 1,422 studies in Cognitive Dysfunction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
VIZAMYL (flutemetamol F 18 injection) is a drug used during Positron Emission Tomography (PET) brain scans. It helps doctors detect the presence of amyloid protein, which is associated with Alzheimer's disease and other conditions affecting memory or thinking. A new formulation of this drug, called GE-287, has been developed. This new formulation may offer advantages for patient tolerability and can be produced more reliably and efficiently.
The aim of the study is to determine whether the new formulation works as well as the current one in identifying amyloid in the brain, how it distributes in the body, and whether it is safe for use. The study will measure how much of the study drug goes to different organs (including the brain, heart, liver, and kidneys) and monitor for any side effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant is surgically sterile (has had documented bilateral oophorectomy, bilateral salpingectomy, hysterectomy, bilateral orchidectomy, and/or vasectomy with confirmation of success), (cessation of menses for more than 1 year), or:
If the participant can become pregnant, the participant must:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GE-287 · Drug: Vizamyl
Drug: Vizamyl · Drug: GE-287
Drug: GE-287 185 MBq (±10%) of GE-287 administered intravenously
Drug: Vizamyl 185 MBq (±10%) of Vizamyl administered intravenously
Drug: Vizamyl 185 MBq (±10%) of Vizamyl administered intravenously
Drug: GE-287 185 MBq (±10%) of GE-287 administered intravenously
Comparison of Standard Uptake Value ratio in frontal and anterior cingulate brain region
Time frame: 90-100 minutes after product administration
Comparison of SUVr in posterior cingulate and precuneus brain region
Time frame: 90-100 minutes after product administration
Comparison of SUVr in lateral temporal brain region
Time frame: 90-100 minutes after product administration
Comparison of SUVr in inferolateral parietal brain region
Time frame: 90-100 minutes after product administration
Comparison of Standard Uptake Value (SUV) in heart
Time frame: 0-60 minutes after product administration
Comparison of SUV in liver
Time frame: 0-60 minutes after product administration
Comparison of SUV in kidneys
Time frame: 0-60 minutes after product administration
Comparison of global brain Centiloid values
Time frame: 90-100 minutes after product administration
Comparison of SUV in heart
Time frame: 105-150 minutes after product administration
Comparison of SUV in liver
Time frame: 105-150 minutes after product administration
Comparison of SUV in kidneys
Time frame: 105-150 minutes after product administration
Comparison of blinded visual image interpretations without quantification
Time frame: 90-100 minutes after product administration
Comparison of blinded visual image interpretations with quantification
Time frame: Time Frame: 90-100 minutes after product administration
Comparison of inter-reader agreement of the blinded visual image interpretations without quantification
Time frame: 90-100 minutes after product administration
Comparison of inter-reader agreement of the blinded visual image interpretations with quantification
Time frame: 90-100 minutes after product administration
Safety: Treatment-emergent adverse event [TEAE] incidence
Time frame: From pre-administration through 24 hours after product administration
Safety: Changes from baseline in blood hematology
Time frame: From pre-administration through 180 minutes after product administration
Safety: Change from baseline in serum biochemistry
Time frame: from pre-administration through 180 minutes after product administration
Safety: changes from baseline in urinalysis
Time frame: from pre-administration through 180 minutes after product administration
Safety: changes from baseline in blood pressure
Time frame: from pre-administration through 180 minutes after product administration
Safety: changes from baseline in heart rate
Time frame: from pre-administration through 180 minutes after product administration
Safety: changes from baseline in respiratory rate
Time frame: from pre-administration through 180 minutes after product administration
Safety: changes from baseline in temperature
Time frame: from pre-administration through 180 minutes after product administration
Safety: changes from baseline in general appearance, rated as normal or abnormal by a qualified healthcare provider.
Time frame: from pre-administration through 180 minutes after product administration
Safety: changes from baseline in examination of the heart, rated as normal or abnormal by a qualified healthcare provider.
Time frame: from pre-administration through 180 minutes after product administration
Safety: changes from baseline in examination of the lungs, rated as normal or abnormal by a qualified healthcare provider.
Time frame: from pre-administration through 180 minutes after product administration
Safety: changes from baseline in 12-lead electrocardiograms [ECGs] heart rate
Time frame: from pre-administration through 180 minutes after product administration.
Safety: changes from baseline in 12-lead electrocardiogram [ECG] heart rhythm
Time frame: from pre-administration through 180 minutes after product administration
Safety: changes from baseline in 12-lead electrocardiogram [ECG] RR interval
Time frame: from pre-administration through 180 minutes after product administration
Safety: changes from baseline in 12-lead electrocardiogram [ECG] PR interval
Time frame: from pre-administration through 180 minutes after product administration
Safety: changes from baseline in 12-lead electrocardiogram [ECG] QRS interval
Time frame: from pre-administration through 180 minutes after product administration
Safety: changes from baseline in 12-lead electrocardiogram [ECG] QT interval
Time frame: from pre-administration through 180 minutes after product administration
Safety: changes from baseline in 12-lead electrocardiogram [ECG] QTc interval
Time frame: from pre-administration through 180 minutes after product administration
Safety: changes from baseline in 12-lead electrocardiogram [ECG] notation of abnormalities
Time frame: from pre-administration through 180 minutes after product administration
Plan to share: No — There is not a plan to make IPD available.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Feb 2027, 4 months after the start.
Of 42 industry-sponsored phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's planned 4 months is below that.
Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.